Advanced

Assessment of CAR- or CD46-Dependent Adenoviral Vector-Mediated TRAIL Gene Therapy in Clinical Adenocarcinoma Lung Cancer Cells

Wang, Yong; Ma, Lingdi; Wang, Shizhong; Bao, Yongyi; Ni, Cheng; Guan, Naifu; Zhao, Jianzhong and Fan, Xiaolong LU (2009) In Oncology 77(6). p.366-377
Abstract
Adenoviral vector-mediated transfer of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be a powerful approach to lung cancer therapy. However, the efficiency of adenoviral vector gene transfer and the sensitivity to TRAIL-induced apoptosis in the context of adenoviral vector gene transfer have yet to be characterized in primary lung cancers. In this study, we investigated the expression of adenoviral receptor CD46 expression in primary lung cancer cells. In contrast to previous reports on enhanced CD46 expression in various types of cancer cells, we show a significantly higher CD46 expression in lung adenocarcinomas compared to lung squamous cell carcinomas. Using Ad5-GFP and Ad5F35-GFP vectors, we demonstrated an... (More)
Adenoviral vector-mediated transfer of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be a powerful approach to lung cancer therapy. However, the efficiency of adenoviral vector gene transfer and the sensitivity to TRAIL-induced apoptosis in the context of adenoviral vector gene transfer have yet to be characterized in primary lung cancers. In this study, we investigated the expression of adenoviral receptor CD46 expression in primary lung cancer cells. In contrast to previous reports on enhanced CD46 expression in various types of cancer cells, we show a significantly higher CD46 expression in lung adenocarcinomas compared to lung squamous cell carcinomas. Using Ad5-GFP and Ad5F35-GFP vectors, we demonstrated an improved gene transfer efficiency in primary lung cancer cells by the Ad5F35 vector. The apoptosis induction effect mediated by Ad5-TRAIL and Ad5F35-TRAIL vector gene transfer was compared in cells from 10 lung adenocarcinomas. Of 5 lung cancers in which apoptosis was induced, 2 had an enhanced effect by Ad5F35-TRAIL vector gene transfer compared to Ad5-GFP. Thus, these results indicate a method to identify TRAIL-sensitive primary lung cancers, which will also facilitate the analysis of resistance mechanisms in lung cancers. Copyright (C) 2010 S. Karger AG, Basel (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
apoptosis-inducing ligand, Tumor necrosis factor-related, Apoptosis, Lung cancer, Gene therapy
in
Oncology
volume
77
issue
6
pages
366 - 377
publisher
Karger
external identifiers
  • wos:000274314900005
  • scopus:73649116040
ISSN
1423-0232
DOI
10.1159/000275831
language
English
LU publication?
yes
id
413bac9d-9693-4385-915a-09f1c017543c (old id 1567840)
date added to LUP
2010-03-24 16:24:07
date last changed
2017-01-01 04:57:34
@article{413bac9d-9693-4385-915a-09f1c017543c,
  abstract     = {Adenoviral vector-mediated transfer of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be a powerful approach to lung cancer therapy. However, the efficiency of adenoviral vector gene transfer and the sensitivity to TRAIL-induced apoptosis in the context of adenoviral vector gene transfer have yet to be characterized in primary lung cancers. In this study, we investigated the expression of adenoviral receptor CD46 expression in primary lung cancer cells. In contrast to previous reports on enhanced CD46 expression in various types of cancer cells, we show a significantly higher CD46 expression in lung adenocarcinomas compared to lung squamous cell carcinomas. Using Ad5-GFP and Ad5F35-GFP vectors, we demonstrated an improved gene transfer efficiency in primary lung cancer cells by the Ad5F35 vector. The apoptosis induction effect mediated by Ad5-TRAIL and Ad5F35-TRAIL vector gene transfer was compared in cells from 10 lung adenocarcinomas. Of 5 lung cancers in which apoptosis was induced, 2 had an enhanced effect by Ad5F35-TRAIL vector gene transfer compared to Ad5-GFP. Thus, these results indicate a method to identify TRAIL-sensitive primary lung cancers, which will also facilitate the analysis of resistance mechanisms in lung cancers. Copyright (C) 2010 S. Karger AG, Basel},
  author       = {Wang, Yong and Ma, Lingdi and Wang, Shizhong and Bao, Yongyi and Ni, Cheng and Guan, Naifu and Zhao, Jianzhong and Fan, Xiaolong},
  issn         = {1423-0232},
  keyword      = {apoptosis-inducing ligand,Tumor necrosis factor-related,Apoptosis,Lung cancer,Gene therapy},
  language     = {eng},
  number       = {6},
  pages        = {366--377},
  publisher    = {Karger},
  series       = {Oncology},
  title        = {Assessment of CAR- or CD46-Dependent Adenoviral Vector-Mediated TRAIL Gene Therapy in Clinical Adenocarcinoma Lung Cancer Cells},
  url          = {http://dx.doi.org/10.1159/000275831},
  volume       = {77},
  year         = {2009},
}